Results 181 to 190 of about 479,258 (314)
Unraveling the mystery of placebo effect in research and practice: An update. [PDF]
Mishra P, Bhargava S.
europepmc +1 more source
n-3 PUFAs for depression: treatment effect or absence-of-placebo effect? [PDF]
Memarpouri A +2 more
europepmc +1 more source
The Placebo Effect on Reading Ability [PDF]
openIl presente studio è nato con l’obiettivo di testare alcuni effetti fisiologici, come la dimensione della pupilla e la frequenza cardiaca, di un paio di occhiali che sono stati progettati per migliorare le capacità di lettura.
LEDRI, MARTINA
core
Objective Osteoporosis causes fractures that further increase the disease burden of rheumatoid arthritis (RA); however, osteoporosis treatment rates remain low. Although several studies have reported that biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large‐scale, real ...
Takafumi Aritomi +30 more
wiley +1 more source
The Power of Belief: Investigating the Placebo Effect in Post-Exercise Recovery Strategies for Football Players. [PDF]
Pernigoni M +5 more
europepmc +1 more source
Editorial: Placebo Effect in Pain and Pain Treatment. [PDF]
Bernstein MH, Blease C, Vase L.
europepmc +1 more source
Objective Regeneration and expansion of Treg by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we investigated whether reversible defects in the Treg–IL‐2 axis emerge in inflammatory myopathies ...
Justus Ohmes +10 more
wiley +1 more source
The Placebo Effect of Insider Dealing Regulation. [PDF]
Enriques L, Alex Lee YH, Romano A.
europepmc +1 more source
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher +12 more
wiley +1 more source

